

# Jessica K Altman

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8132372/publications.pdf>

Version: 2024-02-01

82  
papers

5,641  
citations

172457

29  
h-index

79698

73  
g-index

83  
all docs

83  
docs citations

83  
times ranked

6468  
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparison of myeloid neoplasms with nonclassic 3q26.2/ <i>MECOM</i> versus classic inv(3)/(t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of <i>MECOM</i> activation. <i>Genes Chromosomes and Cancer</i> , 2022, 61, 71-80.	2.8	6
2	A phase I study of the fully human, fragment crystallizable-engineered, anti-CD-33 monoclonal antibody BI 836858 in patients with previously-treated acute myeloid leukemia. <i>Haematologica</i> , 2022, 107, 770-773.	3.5	10
3	Gilteritinib clinical activity in relapsed/refractory <i>FLT3</i> mutated acute myeloid leukemia previously treated with <i>FLT3</i> inhibitors. <i>American Journal of Hematology</i> , 2022, 97, 322-328.	4.1	21
4	Therapy-related myeloid neoplasms with normal karyotype show distinct genomic and clinical characteristics compared to their counterparts with abnormal karyotype. <i>British Journal of Haematology</i> , 2022, 197, 736-744.	2.5	6
5	Clinical outcomes in patients with relapsed/refractory <i>FLT3</i> -mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib. <i>Blood Cancer Journal</i> , 2022, 12, .	6.2	23
6	Venetoclax Plus Gilteritinib for <i>FLT3</i> -Mutated Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2022, 40, 4048-4059.	1.6	73
7	Therapy-related B-cell acute lymphoblastic leukemia in adults has unique genetic profile with frequent loss of TP53 and inferior outcome. <i>Leukemia</i> , 2021, 35, 2097-2101.	7.2	9
8	Intensive versus less-intensive antileukemic therapy in older adults with acute myeloid leukemia: A systematic review. <i>PLoS ONE</i> , 2021, 16, e0249087.	2.5	1
9	Inhibitory effects of Tomivosertib in acute myeloid leukemia. <i>Oncotarget</i> , 2021, 12, 955-966.	1.8	7
10	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021, 127, 4421-4431.	4.1	4
11	The impact of <i>FLT3</i> mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with <i>FLT3</i> mutation-positive relapsed/refractory acute myeloid leukemia. <i>Cancer Medicine</i> , 2021, 10, 797-805.	2.8	7
12	Evorpacept (ALX148), a CD47-Blocking Myeloid Checkpoint Inhibitor, in Combination with Azacitidine: A Phase 1 / 2 Study in Patients with Myelodysplastic Syndrome (ASPEN-02). <i>Blood</i> , 2021, 138, 2601-2601.	1.4	10
13	A Phase 1b/2 Study of the CD123-Targeting Antibody-Drug Conjugate IMG632 As Monotherapy or in Combination with Venetoclax and Azacitidine for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 4440-4440.	1.4	2
14	Safety and Efficacy from a Phase 1b/2 Study of IMG632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia. <i>Blood</i> , 2021, 138, 372-372.	1.4	13
15	American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. <i>Blood Advances</i> , 2020, 4, 3528-3549.	5.2	113
16	Unique morphologic and genetic characteristics of acute myeloid leukemia with chromothripsis: a clinicopathologic study from a single institution. <i>Human Pathology</i> , 2020, 98, 22-31.	2.0	10
17	Gilteritinib Remains Clinically Active in Relapsed/Refractory <i>FLT3</i> Mutated AML Previously Treated with <i>FLT3</i> inhibitors. <i>Blood</i> , 2020, 136, 5-7.	1.4	1
18	Outcomes in Patients with Hematologic Malignancies Infected with Sars-Cov-2: The Northwestern University Experience. <i>Blood</i> , 2020, 136, 14-16.	1.4	1

#	ARTICLE	IF	CITATIONS
19	An integrative approach reveals genetic complexity and epigenetic perturbation in acute promyelocytic leukemia: a single institution experience. <i>Human Pathology</i> , 2019, 91, 1-10.	2.0	6
20	Germline <i>SH2B3</i> pathogenic variant associated with myelodysplastic syndrome/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. <i>American Journal of Hematology</i> , 2019, 94, E231-E234.	4.1	9
21	How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 411-420.	3.8	16
22	Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial. <i>Clinical Cancer Research</i> , 2019, 25, 4898-4906.	7.0	61
23	Rare myeloid sarcoma with <i>KMT2A (MLL)-ELL</i> fusion presenting as a vaginal wall mass. <i>Diagnostic Pathology</i> , 2019, 14, 26.	2.0	7
24	Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. <i>Echocardiography</i> , 2019, 36, 2033-2040.	0.9	9
25	Identification and targeting of novel CDK9 complexes in acute myeloid leukemia. <i>Blood</i> , 2019, 133, 1171-1185.	1.4	26
26	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. <i>American Journal of Hematology</i> , 2019, 94, 111-117.	4.1	21
27	Molecular remission and response patterns in patients with mutant- <i>IDH2</i> acute myeloid leukemia treated with enasidenib. <i>Blood</i> , 2019, 133, 676-687.	1.4	262
28	Role of Racial, Demographic and Socioeconomic Disparities in Treatment Patterns and Outcomes in AML. <i>Blood</i> , 2019, 134, 3413-3413.	1.4	0
29	Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia. <i>American Journal of Hematology</i> , 2018, 93, 213-221.	4.1	81
30	Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 889-903.	10.7	205
31	Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML. <i>New England Journal of Medicine</i> , 2018, 378, 2386-2398.	27.0	1,092
32	A next-generation sequencing-based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations. <i>Blood Advances</i> , 2018, 2, 825-831.	5.2	107
33	Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations. <i>Blood</i> , 2018, 132, 1458-1458.	1.4	4
34	Updated Results from a Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Subjects with Newly Diagnosed Acute Myeloid Leukemia (AML). <i>Blood</i> , 2018, 132, 564-564.	1.4	41
35	Central Regulatory Role for SIN1 in Interferon $\beta$ (IFN $\beta$ ) Signaling and Generation of Biological Responses. <i>Journal of Biological Chemistry</i> , 2017, 292, 4743-4752.	3.4	6
36	Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1/2 study. <i>Lancet Oncology</i> , The, 2017, 18, 1061-1075.	10.7	402

#	ARTICLE	IF	CITATIONS
37	Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. <i>Blood</i> , 2017, 130, 722-731.	1.4	1,173
38	Disease characteristics and prognosis of myelodysplastic syndrome presenting with isolated thrombocytopenia. <i>International Journal of Hematology</i> , 2017, 105, 44-51.	1.6	15
39	Enasidenib in mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML): Results of a phase I dose-escalation and expansion study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 7004-7004.	1.6	0
40	Results of a Phase 3 Study of Elderly Patients with Newly Diagnosed AML Treated with Sapacitabine and Decitabine Administered in Alternating Cycles. <i>Blood</i> , 2017, 130, 891-891.	1.4	6
41	Optimal treatment strategies for high-risk acute promyelocytic leukemia. <i>Current Opinion in Hematology</i> , 2016, 23, 127-136.	2.5	19
42	NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 1505-1512.	4.9	57
43	Acute promyelocytic leukemia: preventing early complications and late toxicities. <i>Hematology American Society of Hematology Education Program</i> , 2016, 2016, 10-15.	2.5	42
44	SNPping away to individualize induction therapy for acute myelogenous leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 742-743.	1.3	0
45	Merestinib blocks Mnk kinase activity in acute myeloid leukemia progenitors and exhibits antileukemic effects in vitro and in vivo. <i>Blood</i> , 2016, 128, 410-414.	1.4	40
46	Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide. <i>British Journal of Haematology</i> , 2015, 171, 471-477.	2.5	36
47	Direct Binding of Arsenic Trioxide to AMPK and Generation of Inhibitory Effects on Acute Myeloid Leukemia Precursors. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 202-212.	4.1	24
48	Central Role of ULK1 in Type I Interferon Signaling. <i>Cell Reports</i> , 2015, 11, 605-617.	6.4	66
49	Adverse Events During Hematopoietic Stem Cell Infusion: Analysis of the Infusion Product. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, e157-e162.	0.4	15
50	Resveratrol enhances the suppressive effects of arsenic trioxide on primitive leukemic progenitors. <i>Cancer Biology and Therapy</i> , 2014, 15, 473-478.	3.4	14
51	Critical Roles for Rictor/Sin1 Complexes in Interferon-dependent Gene Transcription and Generation of Antiproliferative Responses. <i>Journal of Biological Chemistry</i> , 2014, 289, 6581-6591.	3.4	19
52	Regulatory effects of SKAR in interferon $\beta$ signaling and its role in the generation of type I IFN responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 11377-11382.	7.1	11
53	Autophagy Is a Survival Mechanism of Acute Myelogenous Leukemia Precursors during Dual mTORC2/mTORC1 Targeting. <i>Clinical Cancer Research</i> , 2014, 20, 2400-2409.	7.0	90
54	Contemporary Treatment of APL. <i>Current Hematologic Malignancy Reports</i> , 2014, 9, 193-201.	2.3	25

#	ARTICLE	IF	CITATIONS
55	Heritable GATA2 mutations associated with familial AML-MDS: a case report and review of literature. <i>Journal of Hematology and Oncology</i> , 2014, 7, 36.	17.0	25
56	International Randomized Phase III Study of Elacytarabine Versus Investigator Choice in Patients With Relapsed/Refractory Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2014, 32, 1919-1926.	1.6	166
57	First-in Man, Phase 1 Study of CSL362 (Anti-IL3R $\alpha$ / Anti-CD123 Monoclonal Antibody) in Patients with CD123+ Acute Myeloid Leukemia (AML) in CR at High Risk for Early Relapse. <i>Blood</i> , 2014, 124, 120-120.	1.4	50
58	Single Agent Tamibarotene Has Activity in Acute Promyelocytic Leukemia Patients Previously Treated with ATRA and Arsenic Trioxide, but Does Not Produce Durable Responses. <i>Blood</i> , 2014, 124, 3751-3751.	1.4	1
59	Targeting the CXCR4 Pathway: Safety, Tolerability and Clinical Activity of Ulocuplumab (BMS-936564), an Anti-CXCR4 Antibody, in Relapsed/Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 386-386.	1.4	50
60	BL-8040, a Peptidic CXCR4 Antagonist, Induces Leukemia Cell Death and Specific Leukemia Cell Mobilization in Relapsed/Refractory Acute Myeloid Leukemia Patients in an Ongoing Phase IIa Clinical Trial. <i>Blood</i> , 2014, 124, 950-950.	1.4	11
61	Vemurafenib Has Potent Antitumor Activity in Patients with Relapsed/Refractory BRAF Mutant Hairy Cell Leukemia. <i>Blood</i> , 2014, 124, 24-24.	1.4	4
62	Administration of ATRA to newly diagnosed patients with acute promyelocytic leukemia is delayed contributing to early hemorrhagic death. <i>Leukemia Research</i> , 2013, 37, 1004-1009.	0.8	98
63	Acute myeloid leukemia: potential for new therapeutic approaches targeting mRNA translation pathways. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 243-250.	1.6	5
64	Inhibition of Mnk kinase activity by cercosporamide and suppressive effects on acute myeloid leukemia precursors. <i>Blood</i> , 2013, 121, 3675-3681.	1.4	88
65	NME1 and NME2 as markers for myeloid leukemias. <i>Leukemia and Lymphoma</i> , 2012, 53, 1441-1442.	1.3	4
66	A new purpose for an old drug: inhibiting autophagy with clarithromycin. <i>Leukemia and Lymphoma</i> , 2012, 53, 1255-1256.	1.3	5
67	Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Blood Stem-Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Excellent Disease Control and Long-Term Survival Rates. <i>Blood</i> , 2012, 120, 2024-2024.	1.4	0
68	Dose-Intense Etoposide and Cyclophosphamide without Stem Cell Transplantation for the Treatment of Primary Refractory and Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2012, 120, 4314-4314.	1.4	0
69	Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid. <i>Blood</i> , 2011, 118, 1248-1254.	1.4	341
70	Targeting mTOR for the treatment of AML. New agents and new directions. <i>Oncotarget</i> , 2011, 2, 510-517.	1.8	85
71	Busulfan, Cyclophosphamide, and Etoposide (Bu/Cy/VP-16) Is An Effective Conditioning Regimen Prior to Allogeneic or Autologous Stem Cell Transplantation for Primary Refractory or Relapsed Non-Hodgkin's Lymphoma. <i>Blood</i> , 2011, 118, 4499-4499.	1.4	0
72	Negative Regulatory Effects of Mnk Kinases in the Generation of Chemotherapy-Induced Antileukemic Responses. <i>Molecular Pharmacology</i> , 2010, 78, 778-784.	2.3	39

#	ARTICLE	IF	CITATIONS
73	A Randomized Phase 2 Study of Sapacitabine, An Oral Nucleoside Analogue, In Older Patients with MDS Refractory to Hypomethylating Agents. <i>Blood</i> , 2010, 116, 1857-1857.	1.4	3
74	A Population-Based Study In Acute Promyelocytic Leukemia (APL) Suggests a Higher Early Death Rate and Lower Overall Survival Than Commonly Reported In Clinical Trials: Data From the Surveillance, Epidemiology, and End Results (SEER) Program and the New York State Cancer Registry In the United States Between 1992-2007. <i>Blood</i> , 2010, 116, 872-872.	1.4	5
75	Prospects for mTOR targeting in adult T cell leukemia. <i>Leukemia and Lymphoma</i> , 2009, 50, 525-526.	1.3	1
76	How I treat acute promyelocytic leukemia. <i>Blood</i> , 2009, 114, 5126-5135.	1.4	228
77	Regulatory Effects of Mammalian Target of Rapamycin-mediated Signals in the Generation of Arsenic Trioxide Responses. <i>Journal of Biological Chemistry</i> , 2008, 283, 1992-2001.	3.4	40
78	Regulation of Arsenic Trioxide-induced Cellular Responses by Mnk1 and Mnk2. <i>Journal of Biological Chemistry</i> , 2008, 283, 12034-12042.	3.4	35
79	Exploiting the mammalian target of rapamycin pathway in hematologic malignancies. <i>Current Opinion in Hematology</i> , 2008, 15, 88-94.	2.5	32
80	Targeting the mTOR Pathway Suppresses the Growth of Acute Myeloid Leukemia (AML) Progenitors and Enhances Arsenic Trioxide Induced Antileukemic Responses.. <i>Blood</i> , 2006, 108, 1898-1898.	1.4	0
81	Allogeneic Stem Cell Transplantation (AlloSCT) for Relapsed Hodgkin's Lymphoma (HL) Following Autologous Stem Cell Transplantation (AuSCT): Improved Progression-Free Survival (PFS) in Patients with Graft vs Host-Disease (GvHD) Suggests a Graft vs Lymphoma (GVL) Effect.. <i>Blood</i> , 2005, 106, 5455-5455.	1.4	0
82	The molecular basis of acute myeloid leukemia. , 0, , 751-768.		0